The Impact of Adverse Events, Produced by Antibodies Conjugates, on Quality of Life in Patients With Metastatic Breast Cancer: Multicentric, Observational Study (EVA). - Trial NCT06106711
Access comprehensive clinical trial information for NCT06106711 through Pure Global AI's free database. This phase not specified trial is sponsored by Centro di Riferimento Oncologico - Aviano and is currently Not yet recruiting. The study focuses on Metastatic Breast Cancer. Target enrollment is 92 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Centro di Riferimento Oncologico - Aviano
Timeline & Enrollment
N/A
Nov 02, 2023
Sep 30, 2024
Primary Outcome
Adverse events (AEs) arising during treatment and degree of toxicity,Adverse events (AEs) arising during treatment and degree of toxicity,Quality of life of patients during treatment
Summary
The study stems from the need to detect adverse events arising after the administration of
 Antibody-Drug Conjugates (ADCs) used in the treatment of metastatic breast cancer in a real
 life context and to correlate the same with the quality of life reported by patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06106711
Non-Device Trial